784 catalysts tracked
The calendar tells you when.
This tells you how far and which way.
A probability and a two-sided move forecast on every FDA and clinical catalyst, with the evidence behind each score.
$27.99/month. One plan. Cancel any time.
- Companies
- 229
- Next 90 days
- 152
- Scored
- 689
ZYNVA
Toplinehivmab
chronic hepatitis B
57Mild upside
downsidebalancedupside
If it works+64%
If it misses-77%
- Weighted move
- 69.3%
What you get
- Oct 14ZYNVAToplinebias 5769%
- Oct 22QELRAPDUFAbias 7134%
- Nov 03MIRVOAdCombias 3852%
- Nov 19TANEXToplinebias 6288%
- Dec 02VOSKAPDUFAbias 4927%
Every tracked event, scored
The full forward calendar, with a probability and a move forecast on each row.
| Event | Bias | P(win) | Move | Conf. |
|---|---|---|---|---|
| QELRAPDUFA | 71 | 78% | 34% | A |
| TANEXTopline | 62 | 59% | 88% | B |
| ZYNVATopline | 57 | 62% | 69% | B |
| VOSKAPDUFA | 49 | 71% | 27% | C |
| MIRVOAdCom | 38 | 41% | 52% | B |
| HELYXTopline | 31 | 34% | 61% | C |
Sorted by conviction
The whole calendar ranked by lean, so the handful worth your week surface first.
An instrument, not a tip sheet
No buy list, no alert that says go long, no portfolio. Aperture measures the event and the price, shows you both, and stops there.